Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290975774> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4290975774 endingPage "269" @default.
- W4290975774 startingPage "266" @default.
- W4290975774 abstract "ABSTRACT Background: Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options. Immunotherapies, particularly immune checkpoint inhibitors (ICPi), have revolutionized cancer treatment, but their role in glioblastoma is uncertain. Objective: To review the state of immunotherapies in glioblastoma, with an emphasis on recently published ICPi clinical trials. Methods: In this editorial/opinion article, we critically review results of the first generation of trials of ipilimumab, nivolumab and pembrolizumab in glioblastoma, as well as future directions. Results: Expression of PD-L1 is frequent in glioblastoma, ranging from 60-70% of patients. Phase 1 studies of nivolumab with and without ipilimumab, as well as pembrolizumab, showed no new safety concerns in brain tumors, and no neurotoxicity. However, randomized phase 3 trials of nivolumab showed no survival improvements over bevacizumab in recurrent glioblastoma; no role in newly diagnosed disease as a replacement for temozolomide in unmethylated MGMT promoter tumors; and no benefit as an addition to temozolomide in methylated MGMT tumors. However, studies examining post treatment tumor samples have shown signs of increased immunologic response, and occasional long lasting radiographic responses have been seen. A small study of pembrolizumab suggested a potential role as a “neoadjuvant” treatment in resectable recurrent glioblastoma, while other studies are investigating selection of patients with higher mutational burden and novel agents and combinatorial strategies. Conclusion: Despite initial negative trials, immunotherapy remains of high interest in glioblastoma, and many trials are still ongoing. Improving our mechanistic understanding of the immunosuppression and T cell dysfunction induced by both tumor and the CNS microenvironment remains however crucial for the development of successful immunotherapeutic approaches in this disease." @default.
- W4290975774 created "2022-08-13" @default.
- W4290975774 creator A5033270808 @default.
- W4290975774 date "2022-05-01" @default.
- W4290975774 modified "2023-09-26" @default.
- W4290975774 title "Immune-checkpoint inhibitors for glioblastoma: what have we learned?" @default.
- W4290975774 cites W2104885590 @default.
- W4290975774 cites W2134807618 @default.
- W4290975774 cites W2591751045 @default.
- W4290975774 cites W2608424969 @default.
- W4290975774 cites W2767198352 @default.
- W4290975774 cites W2885696745 @default.
- W4290975774 cites W2911752971 @default.
- W4290975774 cites W2911871569 @default.
- W4290975774 cites W2913623258 @default.
- W4290975774 cites W2996809166 @default.
- W4290975774 cites W3000438116 @default.
- W4290975774 cites W3026551532 @default.
- W4290975774 cites W3099035428 @default.
- W4290975774 cites W3101467937 @default.
- W4290975774 cites W3124162597 @default.
- W4290975774 cites W3176579240 @default.
- W4290975774 cites W4214757615 @default.
- W4290975774 cites W4285719527 @default.
- W4290975774 cites W4288066089 @default.
- W4290975774 doi "https://doi.org/10.1590/0004-282x-anp-2022-s129" @default.
- W4290975774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35976319" @default.
- W4290975774 hasPublicationYear "2022" @default.
- W4290975774 type Work @default.
- W4290975774 citedByCount "3" @default.
- W4290975774 countsByYear W42909757742023 @default.
- W4290975774 crossrefType "journal-article" @default.
- W4290975774 hasAuthorship W4290975774A5033270808 @default.
- W4290975774 hasBestOaLocation W42909757742 @default.
- W4290975774 hasConcept C121608353 @default.
- W4290975774 hasConcept C126322002 @default.
- W4290975774 hasConcept C143998085 @default.
- W4290975774 hasConcept C2776694085 @default.
- W4290975774 hasConcept C2777389519 @default.
- W4290975774 hasConcept C2777701055 @default.
- W4290975774 hasConcept C2777802072 @default.
- W4290975774 hasConcept C2778227246 @default.
- W4290975774 hasConcept C2780030458 @default.
- W4290975774 hasConcept C2780057760 @default.
- W4290975774 hasConcept C2780851360 @default.
- W4290975774 hasConcept C2781433595 @default.
- W4290975774 hasConcept C502942594 @default.
- W4290975774 hasConcept C509974204 @default.
- W4290975774 hasConcept C535046627 @default.
- W4290975774 hasConcept C71924100 @default.
- W4290975774 hasConceptScore W4290975774C121608353 @default.
- W4290975774 hasConceptScore W4290975774C126322002 @default.
- W4290975774 hasConceptScore W4290975774C143998085 @default.
- W4290975774 hasConceptScore W4290975774C2776694085 @default.
- W4290975774 hasConceptScore W4290975774C2777389519 @default.
- W4290975774 hasConceptScore W4290975774C2777701055 @default.
- W4290975774 hasConceptScore W4290975774C2777802072 @default.
- W4290975774 hasConceptScore W4290975774C2778227246 @default.
- W4290975774 hasConceptScore W4290975774C2780030458 @default.
- W4290975774 hasConceptScore W4290975774C2780057760 @default.
- W4290975774 hasConceptScore W4290975774C2780851360 @default.
- W4290975774 hasConceptScore W4290975774C2781433595 @default.
- W4290975774 hasConceptScore W4290975774C502942594 @default.
- W4290975774 hasConceptScore W4290975774C509974204 @default.
- W4290975774 hasConceptScore W4290975774C535046627 @default.
- W4290975774 hasConceptScore W4290975774C71924100 @default.
- W4290975774 hasIssue "5 suppl 1" @default.
- W4290975774 hasLocation W42909757741 @default.
- W4290975774 hasLocation W42909757742 @default.
- W4290975774 hasLocation W42909757743 @default.
- W4290975774 hasLocation W42909757744 @default.
- W4290975774 hasOpenAccess W4290975774 @default.
- W4290975774 hasPrimaryLocation W42909757741 @default.
- W4290975774 hasRelatedWork W1787923008 @default.
- W4290975774 hasRelatedWork W2155654588 @default.
- W4290975774 hasRelatedWork W2285109017 @default.
- W4290975774 hasRelatedWork W2466041754 @default.
- W4290975774 hasRelatedWork W2592882046 @default.
- W4290975774 hasRelatedWork W3021504039 @default.
- W4290975774 hasRelatedWork W3185931698 @default.
- W4290975774 hasRelatedWork W3215044659 @default.
- W4290975774 hasRelatedWork W4206362823 @default.
- W4290975774 hasRelatedWork W4289107172 @default.
- W4290975774 hasVolume "80" @default.
- W4290975774 isParatext "false" @default.
- W4290975774 isRetracted "false" @default.
- W4290975774 workType "article" @default.